# EDGAR Filing Document

**Accession Number:** 0002023658
**File Stem:** 0001193125-25-293647
**Filing Date:** 2025-11
**Character Count:** 2618
**Document Hash:** 07fa80de90651f79180bbf3731a67575
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-293647.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001193125-25-293647

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bicara Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0002023658
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 116 HUNTINGTON AVENUE SUITE 703
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-468-4219

**MAIL ADDRESS:**
- **STREET 1:** 116 HUNTINGTON AVENUE SUITE 703
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**VIA EDGAR** 

November 24, 2025

United States Securities and Exchange Commission

Office of Life Sciences

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Bicara Therapeutics Inc.**<br> **Acceleration Request for Registration Statement on Form S-3**<br> **Filed October 3, 2025**<br> **File No. 333-290707** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Bicara Therapeutics Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to November 26, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Kathryn W. Clerici at (617) 570-1363. If you have any questions regarding this request, please contact Kathryn W. Clerici of Goodwin Procter LLP at (617) 570-1363.

---

| |
|:---|
| Sincerely, |
| Bicara Therapeutics Inc. |
| /s/ Claire Mazumdar |
| Claire Mazumdar, Ph.D. |
| Chief Executive Officer |

---

---

| | |
|:---|:---|
| cc: | Ivan Hyep, *Bicara Therapeutics Inc.*<br> Lara Meisner, Esq., *Bicara Therapeutics Inc.*<br> Kingsley L. Taft, Esq. *Goodwin Procter LLP*<br> Gabriela Morales-Rivera, Esq. *Goodwin Procter LLP*<br> Kathryn W. Clerici, Esq., *Goodwin Procter LLP* |

---